Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 7 for:    Recruiting, Not yet recruiting, Available Studies | "Coxsackievirus Infections"

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04111432
Recruitment Status : Recruiting
First Posted : October 1, 2019
Last Update Posted : October 1, 2019
Sponsor:
Collaborators:
Shaanxi Provincial Center for Disease Control and Prevention
Hanbin District Center for Disease Control and Prevention
Information provided by (Responsible Party):
Sinovac Biotech Co., Ltd

Brief Summary:
The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine.

Condition or disease Intervention/treatment Phase
Hand, Foot and Mouth Disease Biological: Concomitant administration of EV71vaccine with EPI vaccines Biological: Single injection of EPI vaccine Biological: EV71 Vaccine only Phase 4

Detailed Description:
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety andimmunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine. 360 healthy infants of 8 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)&measles mumps, and rubella combined live attenuated vaccine on day 0 and EV71 vaccine (second dose)&encephalitis live attenuated vaccine on day 30. The group II receive measles mumps, and rubella combined live attenuated vaccine on day 0 and encephalitis live attenuated vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 372 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine
Actual Study Start Date : July 26, 2019
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group I-EV71 and EPI vaccines Concomitant administration
EV71 Vaccine (intramuscular injection,0.5ml,first dose)/measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and EV71 Vaccine (intramuscular injection, 0.5ml,second dose)/ encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
Biological: Concomitant administration of EV71vaccine with EPI vaccines
The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.

Active Comparator: Group II-EPI vaccine only Single injection of EPI vaccine:
measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
Biological: Single injection of EPI vaccine
The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.

Active Comparator: Group III-EV71 vaccine only EV71 Vaccine only
the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 andday 30 respectively
Biological: EV71 Vaccine only
The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.




Primary Outcome Measures :
  1. The seroconversion rates(SCR) of the EV71 neutralizing antibody 30 days after two dose of EV71 vaccines [ Time Frame: 30 days after two dose of EV71 vaccines ]
    Immunogenicity indicator


Secondary Outcome Measures :
  1. The seroconversion rates(SCR) of the Measles IgG antibody,Rubella 30 IgG antibody and Mumps IgG antibody 60 days after one dose of MMR vaccine [ Time Frame: 60 days after one dose of MMR vaccine ]
    Immunogenicity indicator

  2. The seroconversion rates(SCR) of the Japanese encephalitis neutralizing antibody 30 days after one dose of Encephalitis B vaccine [ Time Frame: 30 days after one dose of Encephalitis B vaccine ]
    Immunogenicity indicator

  3. EV71 neutralizing antibody positive rate 30 days of two dose of EV71 vaccines [ Time Frame: 30 days after two dose of EV71 vaccines ]
    Immunogenicity indicator

  4. The Geometric mean titer (GMT) of the EV71 neutralizing antibody 30 days of two dose of EV71 vaccines [ Time Frame: 30 days after two dose of EV71 vaccines ]
    Immunogenicity indicator

  5. Measles IgG antibody,Rubella 30 IgG antibody and Mumps IgG antibody positive rate 60 days after one dose of MMR vaccine [ Time Frame: 60 days after one dose of MMR vaccine ]
    Immunogenicity indicator

  6. The Geometric mean titer (GMT) of Measles IgG antibody,Rubella 30 IgG antibody and Mumps IgG antibody 60 days after one dose of MMR vaccine [ Time Frame: 60 days after one dose of MMR vaccine ]
    Immunogenicity indicator

  7. The Japanese encephalitis neutralizing antibody positive rate 30 days after one dose of Encephalitis B vaccine [ Time Frame: 30 days after one dose of Encephalitis B vaccine ]
    Immunogenicity indicator

  8. The Geometric mean titer (GMT) of Japanese encephalitis neutralizing antibody 30 days after one dose of Encephalitis B vaccine [ Time Frame: 30 days after one dose of Encephalitis B vaccine ]
    Immunogenicity indicator

  9. Incidence of solicited local or systemic adverse events within 7 days or 14 days after each dose [ Time Frame: 7 days or 14 days after each dose of injection ]
    Safety indicator

  10. The incidences of adverse reactions after each does [ Time Frame: 0-30 days after each dose ]
    After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 or day 0-14 were reported. Unsolicited adverse events on day 0-30 were also reported.

  11. Incidence of serious adverse events (SAEs) during the period of safety monitoring [ Time Frame: 0-30 days after each dose ]
    Serious adverse events (SAEs) will be collected during the period of safety monitoring after each dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteer aged ≥ 8 months;
  • Proven legal identity;
  • Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study.

Exclusion Criteria:

  • Prior vaccination with EV71 vaccine;
  • Prior vaccination with MMR vaccine or vaccine including mumps or measles or mumps or rubella vaccine components;
  • Prior vaccination with Encephalitis B vaccine;
  • Cannot be vaccinated with both arms at the same time;
  • History of hand,foot and mouth disease;
  • History of measles or mumps or rubella or encephalitis B;
  • Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc;
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
  • Autoimmune diseases or immunodeficiency/immunosuppression;
  • Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis;
  • History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy;
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
  • Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months;
  • Receipt of any of the following products:

    1. Blood product within 3 months prior to study entry;
    2. Any live attenuated vaccine within 14 days prior to study entry;
    3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
    4. Any other study drugs within 30 days prior to study entry;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Axillary temperature > 37.0#;
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04111432


Contacts
Layout table for location contacts
Contact: Shaobai Zhang 86-02982695467 maolyzhang@163.com

Locations
Layout table for location information
China, Shaanxi
Hanbin District Center for Disease Control and Prevention Recruiting
Ankang, Shaanxi, China, 725000
Contact: Heng Wu    86-18309153222    174462924@qq.com   
Sponsors and Collaborators
Sinovac Biotech Co., Ltd
Shaanxi Provincial Center for Disease Control and Prevention
Hanbin District Center for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Shaobai Zhang Shaanxi Provincal Center for Disease Control and Preventione

Layout table for additonal information
Responsible Party: Sinovac Biotech Co., Ltd
ClinicalTrials.gov Identifier: NCT04111432     History of Changes
Other Study ID Numbers: EV71-SN-2019-01
First Posted: October 1, 2019    Key Record Dates
Last Update Posted: October 1, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sinovac Biotech Co., Ltd:
Inactivated Enterovirus Type 71 (EV71) Vaccine
Concomitant vaccination
Safety
Immunogenicity
Infant
Additional relevant MeSH terms:
Layout table for MeSH terms
Coxsackievirus Infections
Foot-and-Mouth Disease
Hand, Foot and Mouth Disease
Mouth Diseases
Stomatognathic Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Enterovirus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs